| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
T Z Medical Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gfk Market Measures is a East Hanover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BDC Advisors is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stentys is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.